CompletedNCT01479829
Escitalopram With Celecoxib or Placebo for Depression Related to Bipolarity
About this title
Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
Read the official source — NCT01479829Medication studyAges 21–65United States
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.
- Listed locations
- MaywoodSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: March 23, 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Loyola University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT01479829
- Official title
Show the full official title
Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Maywood
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Loyola University, a university.
Did this study involve medication?
Yes. The study involved medication, including Escitalopram, Celecoxib and Placebo.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.
